title: Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients.
abstract: BACKGROUND
  Endothelial dysfunction is an early feature of atherosclerosis. The relationship between insulin action and hypertriglyceridaemia on endothelial function is still debated.
  
  
  METHODS
  This study was designed to determine the effect of a 3 month treatment with Gemfibrozil (GF) on flow-mediated vasodilatation and insulin sensitivity. Ten type 2 diabetic patients were randomised in crossover, double blind fashion, either to GF, 600 mg b.i.d. or placebo, for 12 weeks. Lipid profile, low-density lipoprotein (LDL) distribution and flotation properties, insulin action and flow-mediated vasodilatation (FMD) by brachial artery ultrasound, were assessed.
  
  
  RESULTS
  GF decreased serum triglyceride (TG) concentration with an absolute difference of 1.79 +/- 1.28 mmol L-1 (P < 0.0016) between active treatment and placebo, and significantly increased serum high-density lipoprotein (HDL) cholesterol (P = 0.0233). No differences were observed in total, intermediate-density lipoproteins (IDL), LDL cholesterol concentration and LDL peak buoyancy between treatments. GF also improved SI, an index of insulin action (P = 0.005). The FMD was 7 +/- 3% in the baseline condition, 7 +/- 2% during placebo and 14 +/- 3% after GF (P < 0.006).
  
  
  CONCLUSIONS
  GF treatment improves both insulin action and flow-mediated vasodilatation in type 2 diabetic patients. The reduction of TG concentration allows the simultaneous correction of two important components of the metabolic syndrome.
authors.affiliation: University of Padova, Padova, Italy, LADSEB CNR, Padova, Italy, Parke-Davis Italia, Lainate, Milan, Italy. angelo.avogaro@unipd.it
authors.forename: A
authors.initials: A
authors.lastname: Avogaro
authors.forename: M
authors.initials: M
authors.lastname: Miola
authors.forename: A
authors.initials: A
authors.lastname: Favaro
authors.forename: L
authors.initials: L
authors.lastname: Gottardo
authors.forename: G
authors.initials: G
authors.lastname: Pacini
authors.forename: E
authors.initials: E
authors.lastname: Manzato
authors.forename: S
authors.initials: S
authors.lastname: Zambon
authors.forename: D
authors.initials: D
authors.lastname: Sacerdoti
authors.forename: S
authors.initials: S
authors.lastname: de Kreutzenberg
authors.forename: T
authors.initials: T
authors.lastname: Piliego
authors.forename: A
authors.initials: A
authors.lastname: Tiengo
authors.forename: S
authors.initials: S
authors.lastname: Del Prato
mesh_terms: D000368:Aged; D001161:Arteriosclerosis / Q000517:prevention & control; D001775:Blood Circulation / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004730:Endothelium, Vascular / Q000187:drug effects; D015248:Gemfibrozil / Q000627:therapeutic use*; D006801:Humans; D015228:Hypertriglyceridemia / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D007333:Insulin Resistance; D014280:Triglycerides / Q000378:metabolism; D014664:Vasodilation / Q000187:drug effects*
chemical_list: D000960:Hypolipidemic Agents; D007328:Insulin; D014280:Triglycerides; D015248:Gemfibrozil